Aptevo Therapeutics Inc (APVO):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Aptevo Therapeutics Inc (APVO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9863
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:37
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Aptevo Therapeutics Inc (Aptevo), a subsidiary of Emergent Biosolutions Inc, is a biotechnology company that develops and commercializes oncology and hematology therapeutics. The company’s only marketed product Ixinity that is indicated to replace the missing clotting factor IX in adults and children with hemophilia B. Its pipeline includes immune-oncology candidates for the treatment metastatic castration-resistant prostate cancer, peripheral T-cell lymphoma (PTCL), hematological malignancies, psoriasis and inflammatory bowel disease, and solid tumors. Aptevo is also developing a lead bispecific antibody candidate in collaboration with Alligator Bioscience AB for the treatment of various types of cancer. The company’s immuno-oncology candidates are built on its proprietary Adaptir platform. Aptevo is headquartered in Seattle, Washington, the US.

Aptevo Therapeutics Inc (APVO) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Aptevo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Aptevo Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Aptevo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Aptevo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Aptevo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Aptevo Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
Aptevo Therapeutics and Alligator Bioscience Enter into Co-Development Agreement 10
Equity Offering 12
Aptevo Therapeutics Plans to Raise up to USD17.5 Million in Public Offering of Shares 12
Emergent BioSolutions Completes Spin-Off of Aptevo Therapeutics 13
Asset Transactions 14
Saol Therapeutics Acquires Hyperimmune Products from Aptevo Therapeuticsuni for USD74.5 Million 14
Aptevo Therapeutics Inc – Key Competitors 15
Aptevo Therapeutics Inc – Key Employees 16
Aptevo Therapeutics Inc – Locations And Subsidiaries 17
Head Office 17
Other Locations & Subsidiaries 17
Recent Developments 18
Financial Announcements 18
Aug 20, 2018: Aptevo Therapeutics deploys Genedata Biologics to streamline Cancer Immunotherapy R&D 18
Aug 09, 2018: Aptevo Therapeutics reports second quarter 2018 financial results 19
May 10, 2018: Aptevo Therapeutics Reports First Quarter 2018 Financial Results 21
Mar 13, 2018: Aptevo Therapeutics Reports 2017 Financial Results and Provides Business Update 23
Nov 09, 2017: Aptevo Therapeutics Reports Third Quarter 2017 Financial Results 25
Aug 10, 2017: Aptevo Therapeutics Reports Second Quarter 2017 Financial Results 27
May 12, 2017: Aptevo Therapeutics Reports First Quarter 2017 Financial Results 28
Mar 31, 2017: Aptevo Therapeutics Reports 2016 Financial Results and Provides Business Update 30
Product News 32
Oct 02, 2017: Aptevo Therapeutics Presents New Data on Enhanced Features of Its Next Generation ADAPTIR Bispecific Platform at the World Bispecific Summit 32
Mar 14, 2017: Aptevo Therapeutics Expands Bispecific Antibody Portfolio 34
Clinical Trials 35
Mar 14, 2017: Aptevo Therapeutics Presents Preclinical Data on New Anti-CD123 ADAPTIR Bispecific Candidate APVO437 at the American Association for Cancer Research 2017 Annual Meeting 35
Other Significant Developments 36
Aug 29, 2017: ImmunoPrecise announces R&D success using the OmniAb® platform to develop fully human antibodies 36
Appendix 37
Methodology 37
About GlobalData 37
Contact Us 37
Disclaimer 37

List of Tables
Aptevo Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Aptevo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Aptevo Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Aptevo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Aptevo Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Aptevo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Aptevo Therapeutics and Alligator Bioscience Enter into Co-Development Agreement 10
Aptevo Therapeutics Plans to Raise up to USD17.5 Million in Public Offering of Shares 12
Emergent BioSolutions Completes Spin-Off of Aptevo Therapeutics 13
Saol Therapeutics Acquires Hyperimmune Products from Aptevo Therapeuticsuni for USD74.5 Million 14
Aptevo Therapeutics Inc, Key Competitors 15
Aptevo Therapeutics Inc, Key Employees 16
Aptevo Therapeutics Inc, Other Locations 17
Aptevo Therapeutics Inc, Subsidiaries 17

List of Figures
Aptevo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Aptevo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Aptevo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Aptevo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Aptevo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Aptevo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Aptevo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Aptevo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Aptevo Therapeutics Inc (APVO):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Costco Wholesale Corporation:企業の戦略・SWOT・財務分析
    Costco Wholesale Corporation - Strategy, SWOT and Corporate Finance Report Summary Costco Wholesale Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Comvita Ltd (CVT):企業の財務・戦略的SWOT分析
    Comvita Ltd (CVT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • VeriFone Systems Inc:企業のM&A・事業提携・投資動向
    VeriFone Systems Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's VeriFone Systems Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A …
  • Aero Precision Industries, Inc.:企業の戦略・SWOT・財務情報
    Aero Precision Industries, Inc. - Strategy, SWOT and Corporate Finance Report Summary Aero Precision Industries, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Allot Communications Ltd. (ALLT):企業の財務・戦略的SWOT分析
    Allot Communications Ltd. (ALLT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Votorantim SA:企業の戦略的SWOT分析
    Votorantim SA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services …
  • Thomson Reuters Corporation:企業の戦略・SWOT・財務分析
    Thomson Reuters Corporation - Strategy, SWOT and Corporate Finance Report Summary Thomson Reuters Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Petroleo Brasileiro SA:企業の戦略・SWOT・財務分析
    Petroleo Brasileiro SA - Strategy, SWOT and Corporate Finance Report Summary Petroleo Brasileiro SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Disco Corp (6146):企業の財務・戦略的SWOT分析
    Disco Corp (6146) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Rigel Pharmaceuticals Inc (RIGL):製薬・医療:M&Aディール及び事業提携情報
    Summary Rigel Pharmaceuticals Inc. (Rigel) is a biotechnology company that discovers and develops innovative small-molecule drugs for patients with immune disorders, hematological disorders, cancer and rare diseases. Its research activities focus on signaling pathways that are critical to disease me …
  • Celgene Corp (CELG)-製薬・医療分野:企業M&A・提携分析
    Summary Celgene Corp (Celgene) is an integrated global biopharmaceutical company that carries out the research, development, manufacture and marketing of novel therapies to treat cancer and immune-inflammatory related diseases through gene and protein regulation. Its product portfolio includes Vidaz …
  • Sejal Glass Limited (SEZAL):企業の財務・戦略的SWOT分析
    Sejal Glass Limited (SEZAL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • KSK Power Ventur plc (KSK):企業の財務・戦略的SWOT分析
    Summary KSK Power Ventur plc (KSK Power) is a power generation company that operates in development, operation, construction, and maintenance of power plants. The company operates through four business segments such as power generation, mineral resources, renewable and asset management, among others …
  • PDL Biopharma, Inc.:企業の戦略・SWOT・財務分析
    PDL Biopharma, Inc. - Strategy, SWOT and Corporate Finance Report Summary PDL Biopharma, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • CONSOL Energy Inc.:企業の戦略・SWOT・財務分析
    CONSOL Energy Inc. - Strategy, SWOT and Corporate Finance Report Summary CONSOL Energy Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • C&C Group plc:企業の戦略・SWOT・財務分析
    C&C Group plc - Strategy, SWOT and Corporate Finance Report Summary C&C Group plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Borges International Group SLU:企業の戦略的SWOT分析
    Borges International Group SLU - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major prod …
  • Eftec AG:企業の戦略的SWOT分析
    Eftec AG - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. Thi …
  • Dawnrays Pharmaceutical (Holdings) Ltd (2348):企業の財務・戦略的SWOT分析
    Summary Dawnrays Pharmaceutical (Holdings) Ltd (Dawnrays) is a manufacturer of cephalosporin antibiotics and specific medicines. The company provides products such as cefoperazone sodium and sulbactam sodium sterile, cefoperazone sodium sterile, ceftazidime sterile, cefixme, ceftriaxone sodium crude …
  • Bharat Road Network Ltd (BRNL):企業の財務・戦略的SWOT分析
    Bharat Road Network Ltd (BRNL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆